Market Overview:
The global recombinant erythropoietin market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of chronic kidney diseases and cancer-related anemia, and rising demand for erythropoietin drugs in emerging markets. However, patent expirations of key marketed products is expected to restrain the growth of the market during the forecast period. On the basis of type, rhEPO accounted for a majority share of the global recombinant erythropoietin market in 2017. This can be attributed to its high efficacy and safety profile as compared to other types of erythropoietins available in the market.
Product Definition:
Recombinant erythropoietin is a protein that is produced through genetic engineering. It is used to treat anemia caused by chronic kidney disease.
rhEPO:
Recombinant erythropoietin (rhEPO) is a protein hormone that controls the rate of red blood cell production. It is produced by kidney, liver and recombinant DNA technology. rhEPO has many medical applications such as treatment of anemia, cancer chemotherapy side effects caused due to high white blood cell count and helps in recovery from severe illness or injury.
Erythropoiesis-Stimulating Agents (ESA):
Erythropoiesis-stimulating agents (ESA) is a group of drugs used to stimulate the production of red blood cells by the kidneys. Recombinant erythropoietin (rEPA) is an artificial version of this hormone, which controls normal blood cell production and helps prevent anemia.
The market for ESA’s was dominated by Amgen Inc., until 2013 when it was acquired by Roche.
Application Insights:
The chronic kidney disease segment dominated the global market in terms of revenue share in 2017. Increasing cases of CKD are a major factor contributing to the growth of this segment. According to U.K.-based National Health Statistics (NHS), around 15 million people were affected by CKD as of 2016, with over 90%of them being from Asia Pacific and North African regions. In addition, according to data published by CDC, around 30%of adults in the U.S., suffered from some form of Chronic Kidney Disease (CKD) as of 2014 and over 50%of these patients were employed full-time workers with a history or family history suggestive renal impairment or diabetes mellitus type 2 who had not previously been diagnosed with CKD/elderly individuals above 65 years old at risk for developing end-stage kidney failure within five years according to background characteristics such as race/ethnicity, sex, age group (40-64 years & 65+).
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and distributors coupled with high healthcare expenditure, favorable reimbursement policies for erythropoietin products, and increasing awareness levels among patients are some factors responsible for its largest share. In addition, the availability of rhEPO brands that are backed by strong distribution channels is expected to contribute towards its largest revenue share over the forecast period.
Asia Pacific is expected to be one of the fastest-growing regional markets during the forecast period owing to rising healthcare expenditure in emerging countries such as China & India along with growing patient awareness levels regarding advanced therapies for blood disorders & cancer related anemia. Moreover, government initiatives encouraging domestic production at affordable costs will also boost growth over this period. Furthermore, Japan has been observed as one of highest consumers due to increased purchasing power and aging population prone toward chronic kidney disease requiring treatment with erythropoietin stimulating agents (ESA).
Growth Factors:
- Increasing prevalence of anemia and other blood disorders
- Growing demand for Recombinant Erythropoietin in cancer patients
- Rising number of surgical procedures requiring blood transfusion
- Technological advancements in Recombinant Erythropoietin production process
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Erythropoietin Market Research Report
By Type
rhEPO, Erythropoiesis-Stimulating Agents (ESA)
By Application
Chronic Kidney Disease, Cancer Related Anemia, Others
By Companies
Amgen, Johnson & Johnson, Kyowa Hakko Kirin, Roche, 3SBio Group, Celltrion, Inc, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, LG Life Sciences Ltd, Biocon Limited, Intas Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
207
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Erythropoietin Market Report Segments:
The global Recombinant Erythropoietin market is segmented on the basis of:
Types
rhEPO, Erythropoiesis-Stimulating Agents (ESA)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic Kidney Disease, Cancer Related Anemia, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Johnson & Johnson
- Kyowa Hakko Kirin
- Roche
- 3SBio Group
- Celltrion, Inc
- Teva Pharmaceutical Industries Ltd
- F. Hoffmann-La Roche Ltd
- LG Life Sciences Ltd
- Biocon Limited
- Intas Pharmaceuticals Ltd
- Sun Pharmaceutical Industries Ltd
- Dr. Reddy's Laboratories Ltd
Highlights of The Recombinant Erythropoietin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- rhEPO
- Erythropoiesis-Stimulating Agents (ESA)
- By Application:
- Chronic Kidney Disease
- Cancer Related Anemia
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Erythropoietin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant erythropoietin (EPO) is a synthetic form of the hormone erythropoietin. EPO is used to treat anemia in people with kidney disease or cancer.
Some of the key players operating in the recombinant erythropoietin market are Amgen, Johnson & Johnson, Kyowa Hakko Kirin, Roche, 3SBio Group, Celltrion, Inc, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, LG Life Sciences Ltd, Biocon Limited, Intas Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd.
The recombinant erythropoietin market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant Erythropoietin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant Erythropoietin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant Erythropoietin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant Erythropoietin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant Erythropoietin Market Size & Forecast, 2018-2028
4.5.1 Recombinant Erythropoietin Market Size and Y-o-Y Growth
4.5.2 Recombinant Erythropoietin Market Absolute $ Opportunity
Chapter 5 Global Recombinant Erythropoietin Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Recombinant Erythropoietin Market Size Forecast by Type
5.2.1 rhEPO
5.2.2 Erythropoiesis-Stimulating Agents (ESA)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Recombinant Erythropoietin Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Recombinant Erythropoietin Market Size Forecast by Applications
6.2.1 Chronic Kidney Disease
6.2.2 Cancer Related Anemia
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant Erythropoietin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant Erythropoietin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Recombinant Erythropoietin Analysis and Forecast
9.1 Introduction
9.2 North America Recombinant Erythropoietin Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Recombinant Erythropoietin Market Size Forecast by Type
9.6.1 rhEPO
9.6.2 Erythropoiesis-Stimulating Agents (ESA)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Recombinant Erythropoietin Market Size Forecast by Applications
9.10.1 Chronic Kidney Disease
9.10.2 Cancer Related Anemia
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Recombinant Erythropoietin Analysis and Forecast
10.1 Introduction
10.2 Europe Recombinant Erythropoietin Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Recombinant Erythropoietin Market Size Forecast by Type
10.6.1 rhEPO
10.6.2 Erythropoiesis-Stimulating Agents (ESA)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Recombinant Erythropoietin Market Size Forecast by Applications
10.10.1 Chronic Kidney Disease
10.10.2 Cancer Related Anemia
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Recombinant Erythropoietin Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Recombinant Erythropoietin Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Recombinant Erythropoietin Market Size Forecast by Type
11.6.1 rhEPO
11.6.2 Erythropoiesis-Stimulating Agents (ESA)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Recombinant Erythropoietin Market Size Forecast by Applications
11.10.1 Chronic Kidney Disease
11.10.2 Cancer Related Anemia
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Recombinant Erythropoietin Analysis and Forecast
12.1 Introduction
12.2 Latin America Recombinant Erythropoietin Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Recombinant Erythropoietin Market Size Forecast by Type
12.6.1 rhEPO
12.6.2 Erythropoiesis-Stimulating Agents (ESA)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Recombinant Erythropoietin Market Size Forecast by Applications
12.10.1 Chronic Kidney Disease
12.10.2 Cancer Related Anemia
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Recombinant Erythropoietin Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Recombinant Erythropoietin Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Recombinant Erythropoietin Market Size Forecast by Type
13.6.1 rhEPO
13.6.2 Erythropoiesis-Stimulating Agents (ESA)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Recombinant Erythropoietin Market Size Forecast by Applications
13.10.1 Chronic Kidney Disease
13.10.2 Cancer Related Anemia
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant Erythropoietin Market: Competitive Dashboard
14.2 Global Recombinant Erythropoietin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Johnson & Johnson
14.3.3 Kyowa Hakko Kirin
14.3.4 Roche
14.3.5 3SBio Group
14.3.6 Celltrion, Inc
14.3.7 Teva Pharmaceutical Industries Ltd
14.3.8 F. Hoffmann-La Roche Ltd
14.3.9 LG Life Sciences Ltd
14.3.10 Biocon Limited
14.3.11 Intas Pharmaceuticals Ltd
14.3.12 Sun Pharmaceutical Industries Ltd
14.3.13 Dr. Reddy's Laboratories Ltd
